Why there's no tested list
A 2025 review that pulled together the BPC-157 research in sports and joint medicine found one small human study and said plainly that no study has measured its side effects in people. In animal models the same review found no acute toxicity, but that covers short periods in animals and says little about a person taking it for weeks. The FDA's staff review adds that in 28-day rat and dog studies, some findings, including changes in blood clotting time and liver markers, were flagged as clinically relevant, and longer studies weren't available.
The FDA reached a similar place. Its briefing document for the July 2026 advisory meeting concluded there is insufficient clinical safety information to characterize BPC-157's safety profile.
What has been reported
| Source | What it describes |
|---|---|
| Animal studies | No acute toxicity; some clotting and liver signals at 28 days |
| FDA briefing, July 2026 | Three reports, cause unclear |
| Online user reports | Injection-site pain, anxiety, palpitations, low mood |
| Our dosage page | Mild redness or irritation at the site |
The same briefing listed three reports of problems after BPC-157 injections. One was a 55-year-old woman with nine days of redness and swelling at the injection site, and another was a 28-year-old man who went to the emergency room with shortness of breath. The agency was careful to say it's unclear whether BPC-157 caused either, since the reports came with limited information and other medications.
The review also noted that online users describe injection-site pain, anxiety, heart palpitations and depression, and it said such effects could be possible with unregulated production or contamination. It didn't show that contamination caused them. It still matters, since a vial's contents are only as good as its lab report, and the FDA's staff said in the same meeting that BPC-157 is "not well-characterized."
What it changes for you
Treat the list as reports, because that's what it is. The practical response is to buy from a vendor that publishes a batch-specific lab report, read it before you open the vial (our guide to reading a COA walks through it), and keep a note of the date, the amount and how you feel, which helps if something does come up. The signs our BPC-157 dosage page lists for stopping a course early are a persistent injection-site reaction, new digestive symptoms that don't resolve and any new symptom you can't explain.
To compare sellers and see who posts lab reports, start with the vendor directory and the price comparison app. The BPC-157 page has the research background. If you're weighing the pill form, see whether BPC-157 works orally, and for the regulatory side, whether BPC-157 is legal.
It's sold for research, and the big human trials haven't been run yet. You knew that, it's why you're reading this and not the label.
Questions people ask
Is BPC-157 safe?
Safety hasn't been established in people. The FDA's staff review said there is insufficient clinical safety information to characterize its safety profile.
What are the side effects of BPC-157 in women?
No study reports results by sex. One of the three cases in the FDA's briefing was a 55-year-old woman with redness and swelling at the injection site, and the agency said it couldn't tell if BPC-157 caused it.
Does BPC-157 cause injection site reactions?
Mild redness or irritation at the site is the common one listed on our BPC-157 dosage page. Anything that persists beyond brief mild redness is a sign people stop.
Can side effects come from a bad vial?
A 2025 review of the BPC-157 research says such effects could be possible with unregulated production or contamination, which is a possibility it raised, not something it showed. A lab report doesn't remove that risk, but it's the first check.
When do people stop BPC-157?
Our dosage page lists a persistent injection-site reaction, new digestive symptoms that don't resolve, and any new symptom you can't explain.
